<DOC>
	<DOCNO>NCT00322348</DOCNO>
	<brief_summary>The primary objective evaluate whether Zoladex 10.8 mg ( 12-weekly ) non-inferior Zoladex 3.6 mg ( 4-weekly ) pre-menopausal woman oestrogen receptor positive advanced breast cancer assessment progression-free survival 24 week . Secondary Objectives compare safety tolerability profile ZOLADEX 10.8 mg ZOLADEX 3.6 mg assessment adverse event ( AEs ) ass goserelin PK Japanese Caucasian participant receive ZOLADEX 10.8 mg assessment goserelin plasma concentration time profile Recruitment study permanently stop 24 December 2007 due slow recruitment . 98 ( v plan 260 ) patient randomise study follow per protocol 2 year</brief_summary>
	<brief_title>Study Zoladex Given Every 12 Weeks Versus Given Every Month Advanced Breast Cancer ( ABC ) Pre-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Premenopausal woman age 18 year histologically/cytologicallyconfirmed oestrogen receptor positive ( ER +ve ) breast cancer World Health Organization ( WHO ) performance status 0 , 1 , 2 Provided write informed consent Treatment tamoxifen hormonal therapy early breast cancer ( EBC ) adjuvant previous 24 week Received radiotherapy within past 4 week History systemic malignancy breast cancer within previous 3 year Estimated survival less 24 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>